- Home
- NXJ vs ORIC Comparison
NXJ vs ORIC Comparison
Compare NXJ & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXJ
- ORIC
- Stock Information
- Founded
- NXJ 1999
- ORIC 2014
- Country
- NXJ United States
- ORIC United States
- Employees
- NXJ N/A
- ORIC N/A
- Industry
- NXJ Finance/Investors Services
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- NXJ Finance
- ORIC Health Care
- Exchange
- NXJ Nasdaq
- ORIC Nasdaq
- Market Cap
- NXJ 492.3M
- ORIC 545.5M
- IPO Year
- NXJ N/A
- ORIC 2020
- Fundamental
- Price
- NXJ $11.70
- ORIC $6.14
- Analyst Decision
- NXJ
- ORIC Strong Buy
- Analyst Count
- NXJ 0
- ORIC 9
- Target Price
- NXJ N/A
- ORIC $18.43
- AVG Volume (30 Days)
- NXJ 74.9K
- ORIC 674.4K
- Earning Date
- NXJ 01-01-0001
- ORIC 05-05-2025
- Dividend Yield
- NXJ 3.27%
- ORIC N/A
- EPS Growth
- NXJ N/A
- ORIC N/A
- EPS
- NXJ N/A
- ORIC N/A
- Revenue
- NXJ N/A
- ORIC N/A
- Revenue This Year
- NXJ N/A
- ORIC N/A
- Revenue Next Year
- NXJ N/A
- ORIC N/A
- P/E Ratio
- NXJ N/A
- ORIC N/A
- Revenue Growth
- NXJ N/A
- ORIC N/A
- 52 Week Low
- NXJ $10.06
- ORIC $5.78
- 52 Week High
- NXJ $12.24
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- NXJ 28.35
- ORIC 34.15
- Support Level
- NXJ $11.66
- ORIC $5.78
- Resistance Level
- NXJ $11.96
- ORIC $8.11
- Average True Range (ATR)
- NXJ 0.10
- ORIC 0.54
- MACD
- NXJ -0.02
- ORIC -0.11
- Stochastic Oscillator
- NXJ 10.00
- ORIC 15.45
About NXJ Nuveen New Jersey Qualified Municipal Fund
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.